CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19
Status:
Completed
Trial end date:
2021-04-28
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of DHODHi (brequinar) as an antiviral via 5
days of treatment of participants with positive COVID-19 and at least one symptom of COVI019
in an out-patient setting. The study is multi-center, randomized, and placebo-controlled.